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wnuk@if-pan.krakow.pl (A.W.); k.kamin@if-pan.krakow.pl (K.K.); kajta@if-pan.krakow.pl (M.K.);
rogoz@if-pan.krakow.pl (Z.R.)
3 Department of Environmental Chemistry, University of Łódź, 163 Pomorska Street, 90-236 Łódź, Poland;
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Abstract: Impaired glutathione (GSH) synthesis and dopaminergic transmission are important
factors in the pathophysiology of schizophrenia. Our research aimed to assess the effects of
l-buthionine-(S,R)-sulfoximine (BSO), a GSH synthesis inhibitor, and GBR 12909, a dopamine
reuptake inhibitor, administered alone or in combination, to Sprague–Dawley rats during early
postnatal development (p5–p16), on the levels of GSH, sulfur amino acids, global DNA methylation,
and schizophrenia-like behavior. GSH, methionine (Met), homocysteine (Hcy), and cysteine (Cys)
contents were determined in the liver, kidney, and in the prefrontal cortex (PFC) and hippocampus
(HIP) of 16-day-old rats. DNA methylation in the PFC and HIP and schizophrenia-like behavior
were assessed in adulthood (p90–p93). BSO caused the tissue-dependent decreases in GSH content
and alterations in Met, Hcy, and Cys levels in the peripheral tissues and in the PFC and HIP.
The changes in these parameters were accompanied by alterations in the global DNA methylation in
the studied brain structures. Parallel to changes in the global DNA methylation, deficits in the social
behaviors and cognitive functions were observed in adulthood. Only BSO + GBR 12909-treated rats
exhibited behavioral alterations resembling positive symptoms in schizophrenia patients. Our results
suggest the usefulness of this neurodevelopmental model for research on the pathomechanism
of schizophrenia.
Keywords: social and cognitive deficits; GSH deficiency; global DNA methylation;
neurodevelopmental model of schizophrenia; sulfur amino acids levels
1. Introduction
Schizophrenia is a chronic, most devastating psychiatric illness affecting about 1% of the
world population [1]. It develops progressively, often remaining undetected during childhood
and adolescence, with the first episodes of psychosis that appear in early adulthood. The symptoms
of the disorder are well characterized and divided into three main categories: positive symptoms
Molecules 2019, 24, 4253; doi:10.3390/molecules24234253 www.mdpi.com/journal/molecules
Molecules 2019, 24, 4253 2 of 27
(delusions, hallucinations, and thought disorder), negative symptoms (lack of motivation and deficits in
social function), and cognitive deficits (impairment of attention, memory, and executive functions) [2].
It is increasingly recognized that schizophrenia is a neurodevelopmental disorder that involves
abnormalities both in the structure and functioning of the brain. However, the mechanism underlying
these pathological changes still remains poorly understood despite intensive studies. According to the
prevailing hypothesis for the etiology of the disease, the structural and functional brain abnormalities
could be initiated during embryonic or early postnatal development by numerous interactions between
genetic and environmental factors [3], detrimental consequences of which appear in adulthood [4,5].
Moreover, since changes in the DNA sequence are only one aspect of the schizophrenia heritability,
researches’ attention has recently been focused on epigenetic mechanism [6–8], i.e., modification of the
regulation and expression of genes, without alterations in DNA sequence itself. These mechanisms
include DNA methylation, histone modification, as well as regulations of RNA molecules [9].
Exploration of factors that initiate changes in DNA methylation [8,10,11] is particularly important
because epigenetic regulation plays a crucial role in the brain development, synaptic plasticity,
and formation of long-term memory [12–15].
Parallel to the above trends, a growing body of experimental data indicates that impaired
redox-regulation and oxidative stress may play a significant role in the pathophysiology of
schizophrenia [16–21]. In support of this view, it has been demonstrated that the level of glutathione
(GSH), the main cellular non-protein antioxidant, and redox regulator [22,23] are decreased in the
cerebrospinal fluid and medial prefrontal cortex (mPFC) of drug-naive schizophrenic patients [24,25]
as well as in the post-mortem striatum and PFC of those treated earlier with antipsychotic
drugs [26,27]. Interestingly, reduction of GSH concentration in schizophrenia seems to be linked to
polymorphisms of genes encoding both catalytic and modifier subunits of γ-glutamate-cysteine ligase
(GCL, EC 6.3.2.2.) [28–30], which is a key enzyme in GSH biosynthesis [31]. Furthermore, a significant
negative correlation between the brain GSH levels [25] and the severity of negative symptoms was
found in schizophrenic patients [32].
In rodents GSH levels can be depleted using the GCL, inhibitor l-buthionine-(S,R)-sulfoximine
(BSO) [33], by using the GSH depleting agent diethyl maleate (DEM) [34], or via manipulation of
genes encoding catalytic or modifier subunits of GCL [35–37]. Using these approaches some authors
have reported on schizophrenia-like symptoms in animals showing numerous morphological and
biochemical abnormalities reminiscent of those observed in patients with schizophrenia [16–18,21,38].
Consistently, referring GSH deficiency to schizophrenia-like symptoms, BSO given chronically into the
cerebral ventricles of adult rats prior to dopamine (DA) administration, produced spatial memory
deficits observed in the Morris water maze [39]. Acute, systemic administration of DEM, induced
a severe reduction in the hippocampal GSH content and impaired short-term synaptic interactions
(paired-pulses) and long-term potentiation without affecting baseline transmission [40]. Treatment of
adult rats with DEM slowed down the acquisition of spatial learning in the Morris water maze [41].
Furthermore, chronic, administration of BSO in combination with an inhibitor of DA transporter (DAT),
the compound GBR 12909, during the early postnatal development (p5–p16) to Osteogenic Disorder
Shionogi (ODS) mutant rats, induced the long-term cognitive deficits, assessed in the novel object
recognition test (NOR) in adulthood [42,43]. Correspondingly, treatment of ODS and Wistar rats during
early postnatal life with BSO alone, evoked impairments of some cognitive functions when learning
and discrimination tasks aimed at assessing spatial working memory performance, were examined
in adulthood in the presence of controlled olfactory cues [44]. The abovementioned clinical and
experimental data seem to confirm the important role of the GSH deficit in the pathogenesis of
schizophrenia, but the molecular mechanisms underlying the pathological changes still remain unclear.
Synthesis of GSH is dependent on both GCL activity, the rate limiting enzyme involved in GSH
biosynthesis, and on substrate availability including the amino acid cysteine (Cys) [45,46]. Cys is a
semi-essential protein amino acid delivered in the diet and also synthesized endogenously via the
transsulfuration pathway from homocysteine (Hcy), which is a key junction metabolite in methionine
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(Met) metabolism [31,47,48]. Moreover, Hcy apart from being metabolized via transsulfuration
pathway can be methylated back to Met [49,50]. The above-described metabolic links between sulfur
amino acids suggest that inhibition of GSH synthesis may lead to disturbances in the functioning of
transsulfuration and re-methylation reactions, and consequently, to alterations in the concentrations of
Met, Hcy, and Cys in different tissues. Interestingly, it was reported that treatment with Met caused a
recrudescence of psychotic symptoms in schizophrenia patients [51], and schizophrenia-like symptoms
in mice [10,11,52,53]. It is also worth remembering that S-adenosylmethionine (SAM) formed as the
first metabolite during the conversion of Met into Hcy, [47], is the principal methyl donor that is crucial
for methylation of key molecules involved in gene expression [6,54]. The most obvious example is
DNA-methylation in cytosine-guanine (CpG) islands located in promoter and regulatory regions of
numerous genes, which controls their transcription [6,8].
In the light of these data, it seems reasonable to suppose that inhibition of GSH synthesis in the
rat body during early postnatal life may be a triggering factor for a cascade of events that starting from
disturbances in the physiological homeostasis of sulfur amino acids and through further changes in the
epigenetic status of some genes in the brain, can ultimately lead to the disclosure of schizophrenia-like
symptoms in adult rats. To confirm this hypothesis, we performed a comprehensive analysis of
the effects of chronic treatment with BSO and GBR 12909, on the content of GSH and sulfur amino
acids (Met, Hcy, and Cys) and the global DNA methylation status, as well as on the expression of
schizophrenia-like behaviors in Sprague–Dawley rats. The rationale for administration of the DAT
inhibitor, compound GBR 12909, was to check whether the increase in the brain level of extracellular
DA during the early postnatal development is sufficient to reveal positive symptoms of schizophrenia
in adulthood, or whether simultaneous disturbances in dopaminergic transmission and GSH synthesis
are required for their occurrence. Like in earlier studies [42–44], both BSO and GBR 12909 were given
between postnatal day 5 and 16, alone or in combination. It is worth noting that at that time both
the rate of rat brain growth and the physiological concentration of the brain GSH were reported to
be the highest [55]. Concentrations of GSH, Met, Hcy, and Cys were measured in peripheral organs,
which play a particular role in the metabolism of GSH and sulfur amino acids, i.e., the liver and kidney
as well as in the brain, especially in its structures involved in the expression of schizophrenia-like
symptoms, i.e., the PFC and hippocampus (HIP) in which relationships between the GSH synthesis
and metabolism of sulfur amino acids are unclear and virtually unexplored. These parameters were
determined in tissue homogenates from 16-day-old Sprague–Dawley males, 4 h after the last BSO,
and/or GBR 12909 doses. The global DNA methylation in the PFC and HIP was measured twice,
4 h after the last doses of the model substances and in adulthood (at 93 days of age). Furthermore,
in adult rats between days 90–92, schizophrenia-like behaviors, corresponding to the negative and
positive symptoms as well as to cognitive deficits observed in schizophrenic patients, were assessed
using appropriate tests. We hope that this set of experiments will shed a new light on the mechanisms
underlying neurodevelopmental disturbances in schizophrenia.
2. Results
2.1. The Effects of Chronic Administration of BSO and GBR 12909 on the Levels of GSH and Sulfur Amino
Acids in the Liver of 16-Day-Old Rats
Figure 1A–D illustrates the effects of chronic treatment with BSO and GBR 12909, alone or
jointly, on the levels of GSH, Cys, Met, and Hcy determined in the liver of 16 days old male
Sprague–Dawley pups, 4 h after the last doses of these compounds. See the Supplementary Materials
for the chromatograms of all the tissue homogenates of the rats.
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Figure 1. The effects of chronic administration of BSO (3.8 mmol/kg s. c., once daily) and the DAT
inhibitor GBR 12,909 (5 mg/kg s. c., every second day), alone or in combination, on the concentrations
of GSH (A), Cys (B), Met (C), and Hcy (D) in the liver of 16-day-old rats. Data expressed in nmole/g
of tissue are presented as the mean ± SEM, n = 7 for each group. Statistical analysis was performed
using a two-way ANOVA; symbols indicate significance of differences according to the Newman–Keuls
post-hoc test, **p < 0.01, ***p < 0.001 vs. control; ###p < 0.001 vs. BSO- and ∆∆∆p < 0.001 vs. GBR
12909-treated groups.
A two-way analysis of variance (ANOVA) performed for GSH concentrations (Figure 1A) in the
studied groups, revealed an overall treatment effect of BSO (F(1,24) = 478.82; p < 0.00001), a lack of
GBR 12909 treatment effect (F(1,24) = 1.470; NS – non significant) and an interaction between these two
model substa ces (F(1,24) = 14.787; p < 0.001). Post hoc omp risons showed that BSO administered
al n or especially in combination with GBR 12,909 decreased the GSH content when compared to the
c tr l group by 66.7% and 76.4%, respectively. In contrast to BSO, GBR 12909 alone increased the
level of GSH by 18.7% of the control value (Figur 1A).
As t Cys levels in the studied groups (Figure 1B), a two-way ANOVA demonstrated no significant
treatments effects of both BSO (F(1,24) = 0.440; NS) and GBR 12,909 (F(1,24) = 4.147; p = 0.052) a d
no interaction between these tw compounds (F(1,24) = 4.235; p = 0.051). Although there were no
statistically significant differenc s in the Cys levels between the analyzed groups, som decr asi g
tendency in its content was observed in rats receiving GBR 12909 alone.
Regarding Met concentrations in the rat liver (Fi ure 1C), a two-way ANOVA revealed significant
treatment effects of BSO (F(1,24) = 13.808; p < 0.001) and GBR 12909 (F(1,24) = 149.75; p < 0.00001) but no
interaction between these compounds (F(1,24) = 0.966; NS). In turn, the same analysis performed for the
hepatic Hcy level (Figure 1D), showed only treatment effect of GBR 12909 (F(1,24) = 91.495; p < 0.00001)
but no effect of BSO (F(1,24) = 1.892; NS) and no interaction between BSO + GBR 12909 (F(1,24) = 0.025,
NS). Post hoc comparisons showed that both BSO and GBR 12909 enhanced Met conce tration in the
rat liver (by 114% and 315% of the control, respectively), but the most pronounced increase i the et
level was observed when these compounds were administered j intly (by 381.5% of the control level;
Figure 1C). In contrast to Met, the Hcy levels were significa tly decreased in groups of rats receiving
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GBR 12909 alone or BSO + GBR 12909 compared to the control (by 65.1% and 75.3%, respectively;
Figure 1D).
2.2. The Effects of Chronic Administration of BSO and GBR 12909 on the Levels of GSH and Sulfur Amino
Acids in the Kidney of 16-Day-Old Rats
Similarly as in the liver, the changes in the levels of GSH, Cys, Met, and Hcy were examined in the
kidney of 16-day-old pups treated chronically with BSO and GBR 12909, alone or jointly (Figure 2A–D).
Molecules 2019, 24, x 5 of 27 
 
significantly decreased in groups of rats receiving GBR 12909 alone or BSO + GBR 12909 compared 
to the control (by 65.1% and 75.3%, respectively; Figure 1D). 
2.2. The Effects of Chronic Administration of BSO and GBR 12909 on the Levels of GSH and Sulfur Amino 
Acids in the Kidney of 16-Day-Old Rats 
Similarly as in the liver, the changes in the levels of GSH, Cys, Met, and Hcy were examined in 
the kidney of 16-day-old pups treated chronically with B O and GBR 12909, alon  or jointly (F gur  
2A–D). 
 
Figure 2. The effects of chronic administration of BSO and GBR 12909, alone or in combination, on 
the levels of GSH (A), Cys (B), Met (C), and Hcy (D) in the kidney of 16-day-old rats. Data expressed 
in nmole/g of tissue are presented as the mean ± SEM, n = 7–8 for each group. Statistical analysis was 
performed using a two-way ANOVA; symbols indicate significance of differences according to the 
Newman–Keuls post-hoc test, **p < 0.01, ***p < 0.001 vs. control; ###p < 0.001 vs. BSO-; and ∆∆∆p < 0.001 
vs. GBR 12909-treated groups. 
A two-way ANOVA performed for GSH, Cys, and Met revealed a general treatment effect of 
BSO (for GSH F(1,24) = 81.694, p < 0.00001; for Cys F(1,28) = 285.51, p < 0.00001; for Met F(1,28) = 12.576, p < 
0.002) but a lack of treatment effect of GBR 12909 (for GSH F(1,24) = 2.954, NS; for Cys F(1,28) = 0.119, NS; 
for Met F(1,28) = 1.371; NS) and no interactions between these model substances referring to these 
parameters (for GSH F(1,24) = 0.308, NS; for Cys F (1,28) = 0.441, NS; for Met F(1,28) = 3.490; p = 0.07). As a 
two-way ANOVA for the Hcy level in the rat kidney was non-significant, the post-hoc analysis of 
this parameter was not performed (Figure 2D). 
In general, the levels of GSH in the kidney of rats treated with BSO alone or in combination with 
GBR 12909 were distinctly reduced (by 49% and 30% of control value, respectively; Figure 2A). In 
parallel to the declines in GSH content, almost similar decreases in the Cys concentration were 
observed in these groups of rats (by 43% for BSO and 41% for BSO + GBR; Figure 2B) while Met 
Figure 2. The effects of chronic administration of BSO and GBR 12909, alone or in combination, on the
levels of GSH (A), Cys (B), Met (C), and Hcy (D) in the kidney of 16-day-old rats. Data expressed in
nmole/g of tissue are presented as the mean ± SEM, n = 7–8 for each group. Statistical analysis was
performed using a two-way ANOVA; symbols indicate significance of differences according to the
Newman–Keuls post-hoc test, **p < 0.01, ***p < 0.001 vs. control; ###p < 0.001 vs. BSO-; and ∆∆∆p < 0.001
vs. GBR 12909-treated groups.
A two-way ANOVA performed for GSH, Cys, and Met revealed a general treatment effect of
BSO (for GSH F(1,24) = 81.694, p < 0.00001; for Cys F(1,28) = 285.51, p < 0.00001; for M t F(1,28) = 12.576,
p < 0.002) but a lack of treatment effect of GBR 12909 (for GSH F(1,24) = 2.954, NS; for Cys F(1,28) = 0.119,
NS; for Met F(1,28) = 1.371; NS) and no interactions between these model substance referring to these
parameters (for GSH F(1,24) = 0.308, NS; for Cys F (1,28) = 0.441, NS; for Me F(1,28) = 3.490; p = 0.07).
As two-way ANOVA for the Hcy level in the rat kidney was non-significant, the post-hoc analysis of
his parameter was not p rformed (Figure 2D).
In general, the levels of GSH in the kidney of rats treated with BSO alone or in combination
with GBR 12909 were di tinctly reduc d (by 49% and 30% of control value, respectively; Figure 2A).
In parallel to the eclines in GSH content, almost similar decreases in the Cys concentration were
observed in these groups of rats (by 43% for BSO and 41% for BSO + GBR; Figure 2B) while Met levels
increased significantly (by 32% and 27%, respectively, Figure 2C). Chronic administration of GBR
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12,909 alone did not change significantly the levels of GSH and Cys, only Met content showed some
increasing tendency in comparison to its value in the control group (Figure 2A–C).
2.3. The Effects of Chronic Administration of BSO and GBR 12909 on the Levels of GSH and Sulfur Amino
Acids in the Brain Structures of 16-Day-Old Rats
A two-way ANOVA performed for GSH and Met concentrations in the PFC of male
Sprague–Dawley pups treated chronically with BSO and GBR 12909, alone and jointly (Figure 3A,C)
demonstrated a significant treatment effect of BSO (for GSH F(1,28) = 28.72, p < 0.00001; for Met
F(1,28) = 45.331; p < 0.0001) but a lack of treatment effect of GBR 12909 (for GSH F(1,28) = 0.10, NS; for Met
F(1,28) = 1.42; NS) and no interaction between BSO and GBR 12909 (for GSH F(1,28) = 0.28, NS; for Met
F(1,28) = 2.31; NS) for these parameters. The same analysis carried out in four groups of 16-day-old rats
for the Cys content (Figure 3B) revealed an overall treatment effects of BSO (F(1,28) = 44.96, p < 0.00001)
and GBR 12909 (F(1,28) = 6.023, p < 0.05) as well as an interaction between these model substances
(F(1,28) = 12.568; p < 0.001). In turn, a two-way ANOVA carried out for Hcy concentration in the
PFC showed a treatment effect of GBR 12909 (F(1,28) = 7.536, p < 0.01), no treatment effect of BSO
(F(1,28) = 1.059, NS), and a lack of interaction between these two compounds (F(1,28) = 3.636, p = 0.07).
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GBR 12909 alone did not affect GSH level in this structure. However, chronic administration of BSO, 
Figure 3. The effects of chronic administration of BSO and GBR 12909, alone and in combination, on the
levels of GSH (A), Cys (B), Met (C), and Hcy (D) in the prefrontal cortex (PFC) of 16-day-old rats. Data
expressed in nmole/g of tissue are presented as the mean± SEM, n = 8 for each group. Statistical analysis
was performed using a two-way ANOVA; symbols indicate significance of differences according to the
Newman–Keuls post-hoc test, **p < 0.01, ***p < 0.001, vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001 vs.
BSO- and ∆∆p < 0.01, ∆∆∆p < 0.001 vs. GBR 12909-treated groups.
Post-hoc analysis demonstrated that in the PFC, BSO alone or jointly with GBR 12909 caused
small but statistically significant decreases in the GSH content (by ca. 7% of the control; Figure 3A).
GBR 12909 lone did not affect GSH l vel in this structure. However, chronic admi istration of BSO,
, or BSO + GBR 12909 markedly increased Cys concentrations by 47.5%, 28.5%, and 42.2% of
the control value, respectively (Figure 3B). In turn, the Met level was reduced both in rats receiving
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BSO alone and jointly with GBR 12909 by 18.5% and 19.7% of the control value, respectively (Figure 3C)
while Hcy concentration was increased only in the GBR 12909-treated group (Figure 3D).
In the HIP, a two-way ANOVA performed for GSH revealed a significant treatment effect of BSO
(F(1,28) = 12.12, p < 0.002) and GBR 12909 (F(1,28) = 8.03; p < 0.01) as well as an interaction of BSO +
GBR 12909 (F(1,28) = 5.20; p < 0.05; Figure 4A). In the case of Cys, this analysis showed only treatment
effect of BSO (F(1,28) = 30.963; p < 0.000001) but a lack effect of GBR 12909 (F(1,28) = 1.055; NS) and
no interaction between model compounds (F(1,28) = 3.565; p = 0.07; Figure 4B). A two-way ANOVA
performed for the Met level in the HIP showed a lack of treatment effect of BSO (F(1,28) = 0.194; NS) but
a significant treatment effect of GBR 12909 (F(1,28) = 7.888, p < 0.05), and an interaction between BSO
and GBR 12909 (F(1,28) = 27.622; p < 0.00001). This analysis performed for the hippocampal Hcy level
revealed only a significant treatment effect of GBR 12909 (F(1,28) = 30.936, p < 0.0001) but there was no
treatment effect of BSO and no interaction between these compounds.
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Post-hoc comparisons showed that in the HIP, BSO administered alone or jointly with GBR 
12909 did not change the level of GSH, while GBR 12909 alone caused a small but statistically 
significant increase in its content (by 8.5% of the control value; Figure 4A). However, administration 
of BSO alone or in combination with GBR 12909 enhanced the concentration of Cys in this structure 
Figure 4. The effects of chronic administration of BSO and GBR 12909, alone or in combination, on the
levels of GSH (A), Cys (B), Met (C), and Hcy (D) in the HIP of 16-day-old rats. Data expressed in
nmole/g of tissue are presented as the mean ± SEM, n = 8 for each group. Statistical analysis was
performed using a two-way ANOVA; symbols indicate significance of differences according to the
Newman–Keuls post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001 vs. control; #p < 0.05; ##p < 0.01,
###p < 0.001 vs. BSO-; and ∆∆p < 0.01, ∆∆∆p < 0.0 vs. GBR 12909-treated groups.
Post-hoc comparisons showed that in the HIP, BSO administered alone or jointly with GBR 12909
did not change the level of GSH, while GBR 12909 alone c used a small but statistical significant
increase in its content (by 8.5% of the control value; Figure 4A). However, a ministration of BSO alone
or in comb ation with GBR 12909 enhanced the concentration of Cys in this structure by 34.9% and
30.9% of the c ntrol value, respectively (Figure 4B). As to the Met lev l in he HIP, its concentrations in
groups of rats receiving only BSO or GBR 12909 were significantly higher than in the control group
by 37.5% and 62.7%, respectively. However, after the combined treatment, this effect was statistically
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non-significant when compared to control (Figure 4C). As to the Hcy content in the HIP, both GBR
12909 administered alone or jointly with BSO distinctly increased its level by 65.7% and 49.2% of the
control value, respectively (Figure 4D).
2.4. The Effects of Chronic Administration of BSO and GBR 12909 on the Levels of the Global DNA
Methylation in the PFC and HIP of 16-Day-Old Rats
The global DNA methylation in the PFC and HIP of 16-day-old rats was determined 4 h after
administration of the last doses of BSO and GBR 12909, alone or jointly (Figure 5A,B).
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Figure 5. The effects of chronic administration of BSO and GBR 12909, alone or in combination,
on th global DNA methylat on in the PFC (A) and HIP (B) of 16-day-old rats. Statistical analysis
was performed using a two-way ANOVA; symbols indicate significance of differences according to
the Newman–Keuls post-hoc test, *p < 0.05, **p < 0.01 vs. control; #p < 0.05, ##p < 0.01 vs. BSO-;
and ∆p < 0.05, ∆∆p < 0.01 vs. GBR 12909-treated groups.
In the PFC, a two-way ANOVA revealed a significant interaction of BSO + GBR 12909
(F(1,19) = 15.258, p < 0.001) but no treatment effects of BSO (F(1, 19) = 0.01, NS) or GBR 12909 (F(1,19) = 0.23,
NS) administered separately. In the HIP, the same analysis showed the overall treatment effects of BSO
(F(1,17) = 4.831, p < 0.05) and GBR 12909 (F(1,17) = 5.435, p < 0.05) administered separately as well as an
interaction of BSO + GBR 12909 (F(1,17) = 7.456, p < 0.02). Post-hoc analysis showed that the global DNA
methylation in the PFC of rats receiving BSO or GBR 12909 alone was significantly decreased while in
group treated with BSO + GBR 12909 it was maintained at the control level (Figure 5A). In contrast
to the PFC, in the HIP joint treatment with BSO + GBR 12909 increased the gl bal DNA methylatio
when compared to the level of DNA methylation in the control group (Figure 5B).
2.5. The Effects of Chronic Administration of BSO and GBR 12909 during the Early Postnatal Life on the
Expression of Schizophrenia-Like Behavior in Adulthood
Behavioral tests (social interaction test, SIT; n vel object recognition test, NOR; and open field test,
OFT) were performed in groups of adult rats (90–92 days old), which were treated with BSO and GBR
12909, alone and in combination between the postnatal days p5 and p16.
2.5.1. Social Interaction Test (SIT)
Social behavior was assessed in 90 days old rats by means of two parameters, i.e., the total time
spent in social interactions and the number of these interactions (Figure 6A,B).
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A two-way ANOVA performed for the total time spent in social interactions revealed an overall
treatment effect of BSO (F(1,20) = 35.677, p < 0.001); a lack of treatment effect of GBR 12909 (F(1,20) = 3.163,
p = 0.09) and no interaction betwe n these m del compounds (F(1,20) = 2.453, NS). The same analysis
carried out for the number of interactions demonstrated only a significant treatment effect of BSO
(F(1,20) = 31.750, p < 0.001).
Post-hoc analysis showed that rats administered BSO alone or jointly with GBR 12909 spent
much less time in social interactions (by 18% and 31.6%, respectively) when compared to value of
this parameter in the control group (Figure 6A). Consequently, in both these groups the number of
episod s (contacts) between two rats was also lower (by 29.5% and 39.3%) than betw en the control
rats (Figur 6B).
2.5.2. Novel Object Recognition Test (NOR)
In order to check whether BSO and GBR 12909 administered chronically, alone or jointly during
the early postnatal life, induce the impairment of cognitive functions in adulthood, the NOR test was
performed on the next day after SIT.
During the acquisition trial (session T1) rats from all examined groups spent equal time exploring
two identical objects (A1 and A2; Figure 7A). In the retention trial (session T2) only control rats
and those receiving GBR 12909 alone explored the novel object significantly longer than the familiar
one (p < 0.001) while in groups treated with BSO alone or jointly with GBR 12909 these objects were
explored with the similar intensity (Figure 7B). A two way ANOVA performed for the recognition
index revealed a significant treatment effect of BSO (F(1,36) = 35.677, p < 0.001) but a lack effect of GBR
12909 (F(1,36) = 3.800, p = 0.059) and no interaction between these model compounds (F(1,36) = 0.131,
NS). Post hoc comparison showed that the values of the recognition indexes in groups of rats receiving
BSO alone or jointly with GBR 12909 were significantly decreased when compared to the control group
(by 24.6 and 30.1%, respectively; Figure 7C).
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Figure 7. The effects of chronic administration of BSO and GBR 12909, alone or in combination, during
the early postnatal life on cognitive functions assessed in adult 91-day-old rats in the novel object
recognition test (NOR) test. (A) Effects of the examined model compounds on exploration of two
identical objects in the acquisition trial (session T1). (B) Effects of the examined model compounds
on exploration of a novel and a familiar object in the retention trial (session T2). (C) Effects of the
examined model compounds on the recognition index. Data are presented as the mean ± SEM, n = 10
for each group. Letters indicate statistically significant differences between the exploration time of a
familiar and a novel object in the session T2 within each studied group, according to the Student’s
t-test for independent samples, aap < 0.001 vs. object A. Statistical analysis of recognition index was
performed using a two-way ANOVA; symbols indicate significance of differences according to the
Newman–Keuls post-hoc test, ***p < 0.001, vs. control; ###p < 0.001 vs. BSO-; and ∆∆∆p < 0.001 vs. GBR
12909-treated groups.
2.5.3. Open Field Test (OFT)
On the 92nd day of postnatal life, the exploratory behavior in the open field (time of walking,
ambulation, peeping, and rearing) was examined in all studied groups (Figure 8).
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Figure 8. The effects of chronic administration of BSO and GBR 12909, alone or in combination, during
the early postnatal life on the exploratory behavior in the open field measured in the adulthood;
(A) time of walking, (B) ambulation, (C) peeping, and rearing. Statistical analysis was performed using
a two-way ANOVA; symbols indicate significance of differences according to the Newman–Keuls
post-hoc test, ***p < 0.001, vs. control; #p < 0.05, ###p < 0.001 vs. BSO-; and ∆∆∆p < 0.001 vs. GBR
12909-treated group.
A two-way ANOVA for the time of walking revealed a significant treatment effect of BSO
(F(1,36) = 61.805, p < 0.0001), no treatment effect of GBR 12909 (F(1,36) = 0.632, NS) and an interaction
between BSO + GBR 12909 (F(1,36) = 66.522, p < 0.0001). The same analysis carried out for the number of
sector crossings (ambulation) also demonstrated a treatment effect of BSO (F(1,36) = 30.048, p < 0.0001),
a lack effect of GBR 12909 (F(1,36) = 2.067, NS), and a significant interaction between these model
compounds (F(1,36) = 17.087, p < 0.0002) regarding this parameter. Only for the number of peeping and
rearing episodes, a two way ANOVA showed significant treatment effects of both BSO (F(1,36) = 19.024,
p < 0.0001) and GBR 12909 (F(1,36) = 7.183, p < 0.01) as well as a marked interaction (F(1,36) = 19.952,
p < 0.0001) between these compounds. Post hoc comparison of the studied groups showed that chronic
combined administration of BSO and GBR 12909 during the early postnatal life (p5–p16) resulted in
adulthood in the prolongation of the time of walking (Figure 8A) and in the increases in the numbers
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of sector crossings (Figure 8B) as well as the rearing and peeping episodes (Figure 8C). Interestingly,
only in the group receiving GBR 12909 alone during the early postnatal development, the time of
walking assessed in adulthood was distinctly decreased compared to the control and BSO-treated
groups (Figure 8A).
2.6. The Effects of Chronic Administration of BSO and GBR 12909 during the Early Postnatal Life on the Levels
of the Global DNA Methylation in the PFC and HIP in Adult Rats
After completing the above described behavioral tests, rats were killed and the global DNA
methylation was determined in the PFC and HIP (Figure 9).
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on the global DNA methylation in the PFC (A) and hippocampus (HIP; B) of adult 93-day-old rats.
Statistical analysis was performed using a two-way ANOVA; symbols indicate significance of differences
according to the Newman–Keuls post-hoc test, **p < 0.01, vs. control and #p < 0.05, ##p < 0.01 vs.
BSO-treated group.
In the PFC, a two-way ANOVA revealed an overall treatment effect of BSO (F(1,20) = 5.854, p < 0.05)
and an interaction of BSO + GBR 12909 (F(1,20) = 10.501, p < 0.01) but a lack treatment effect of
GBR 12909 alone (F(1,20) = 3.997, p = 0.059) while in the HIP, only a significant interaction of these
model compounds was found (F(1,20) = 11.423, p < 0.01) but there were no treatment effects of BSO
(F(1,20) = 3.591, p = 0.07) and GBR 12909 (F(1,20) = 1.750, NS) alone. Post hoc comparisons showed that
in the group of rats receiving BSO during early development, the global methylation of DNA assessed
in adulthood (93th day of age) was significantly enhanced in the PFC (by 45.5%) while in the HIP it
was distinctly reduced (by 31.8%) when compared to the control group (Figure 9A,B).
3. Discussion
In order to facilitate interpretation of the results, the discussion was divided into sections and the
potential mechanisms responsible for changes reported in this work described in relation schizophrenia
patients. This division was to assist in reporting the effects of BSO and GBR 12909, administered alone
or jointly, on GSH, Cys, Met, and Hcy contents in the examined peripheral tissues (liver and kidneys),
and selected brain structures (PFC and HIP).
3.1. Impact of BSO and GBR 12909 on GSH Levels in the Studied Tissues
In our study, chronic administration of BSO and GBR 12909, alone or jointly, differently affected
the levels of GSH measured in the liver, kidney, and the chosen brain structures in 16 days old rats.
The most pronounced decreases in the GSH levels were observed in the liver, moderate in the kidney,
and relatively small, but statistically significant, in the PFC. Interestingly, BSO treatment did not change
the content of GSH in the HIP, keeping it at the level of the control group. The action of BSO both
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in the kidney and in the brain structures studied seems to indicate that some additional factors can
modulate GSH synthesis in these tissues. These factors may include the tissue-specific utilization of
Cys-containing dipeptides as direct substrates for GSH synthesis [46,56,57].
It is well known that BSO inhibits only the first step of GSH synthesis, that is the GCL-
catalyzed reaction during which glutamate and Cys form the dipeptide γ-glutamylcysteine (γ-GluCys).
The second step of GSH synthesis, i.e., the glutathione synthetase-(GS)-catalyzed reaction during which
γ-GluCys is coupled with glycine thus forming GSH, is not inhibited by BSO. Despite the general
rule that GSH is synthesized in all cell types from its precursor amino acids in a two-step reaction,
the renal and brain cells can also use γ-GluCys as a direct substrate for GSH synthesis, and in this
way, they can bypass the first reaction catalyzed by GCL [46,56–58]. In addition to the enzymatic
activity of GCL, γ-GluCys formation in some tissues is closely linked to the activity of γ-glutamyl
transpeptidase (γ-GT), the only extracellular-located enzyme that is capable of breaking down the
extraordinary γ-peptide bond within the GSH molecule [59,60]. In the rat kidney, a very high activity
of γ-GT, much higher than in other tissues, is mainly responsible for the maintenance of particularly
high concentration of Cys [61,62], which in the extracellular space occurs in the disulfide form as
cystine (Cys)2. During the extracellular degradation of GSH by renal γ-GT, the released γ-glutamyl
moiety is transferred to the amino acid acceptor, i.e., (Cys)2, forming γ-glutamylcystine (γ-Glu(Cys)2)
that after being taken up into cells is reduced to the dipeptide γ-GluCys, and then combined with
glycine to form a GSH molecule in the reaction catalyzed by GS [56]. The above-described alternative
pathway of GSH synthesis suggests that in the kidney even under conditions of GCL inhibition,
the synthesis of this antioxidant may still be continued, but with a much lower efficiency due to a
smaller pool of the extracellular GSH. This reasoning can explain why in the BSO-treated groups in
our study, the decrease in GSH content in the rat kidney was significantly smaller than in the liver,
which mainly uses precursor amino acids for GSH synthesis and is characterized by both much lower
γ-GT activity and Cys concentration [59]. Consistently with the above result, it was demonstrated that
acute administration of γ-GluCys in the presence of BSO enhanced the GSH level in the rat kidney [56].
Like in the kidney, the intracerebroventricular injection of γ-GluCys to the BSO-pretreated rats, also
effectively increased GSH concentration in the substantia nigra and brainstem, but not in the cortex [63].
The latter study indicates that the use of γ-GluCys for GSH synthesis in the rat brain is dependent on
the specificity of a given region of the brain.
Regarding the concentration of GSH in the brain, in the PFC of BSO-treated animals, a small but
significant decrease in its content was observed, whereas in the HIP, GSH levels were unchanged.
These results are in contradiction with earlier chronic BSO effects in 16-day-old mutant ODS rats,
in which the same BSO dose as in our study, caused a nearly 50% drop in GSH content both in the PFC
and HIP [64]. The reason for this discrepancy is unknown, but it is likely that Sprague–Dawley and
ODS rats may differ in the basic permeability of the blood brain barrier (BBB) for BSO. On the other
hand, it was demonstrated that in adult mice treated with a single dose of BSO, in response to the
declines in GSH content in the liver and kidney, distinct increases in GSH levels were found either in
the whole brain [65] or only in the cerebellum [66]. Considering our results obtained in 16-day-old
Sprague–Dawley rats treated chronically with BSO, in the context of the above presented data, it is
reasonable to suspect that the concentration of GSH in the PFC and HIP may have been modified in
a specific manner depending on the structure, in response to a drastic drop in the hepatic and renal
levels of GSH. As to the impact of GBR 12909 alone on the levels of GSH in the studied tissues, its
chronic administration increased GSH concentration in the liver and HIP, while in the kidney and PFC,
GSH was maintained at the control level. However, the effects of the combined treatment with BSO +
GBR 12909 on GSH levels in these tissues were almost the same as that exerted by BSO alone.
3.2. Impact of BSO and GBR 12909 on Sulfur Amino Acid Levels in the Peripheral Tissues
The alterations in GSH content in the studied tissues were paralleled by distinct changes in the
concentrations of sulfur amino acids, i.e., Cys, Met, and Hcy. Under physiological conditions, the liver
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takes up Cys and Met from the plasma as well as releases these amino acids to the circulation. In the
human liver, almost 50% of Cys incorporated into the GSH molecule arises from the Met metabolite
Hcy as a result of the transsulfuration reaction [49,67], while the remainder comes from the breakdown
of proteins delivered in the diet.
3.2.1. Modifications in Cys Concentrations
Concentrations of Cys determined in the liver of 16-day-old rats 4 h after the last chronic dose of
BSO or combination of BSO + GBR 12909 were close to that in the control, although in such conditions,
due to the insufficient use of this amino acid for GSH synthesis, an increase in the Cys content would be
expected. Consistently with the above guess, Standeven and Wetterhahn [68] previously demonstrated
that the hepatic Cys level was nearly doubled 20 min after acute BSO administration, but was not
significantly different from control at later time points. However, in our study, regardless of the
time of Cys determination, the lack of statistically significant changes in the Cys level in the liver of
rats treated chronically with BSO alone paralleled by the increased Met content suggests shifting the
balance between the transsulfuration and re-methylation of Hcy, in favor of re-methylation reaction.
This shift in balance between these two metabolic pathways became even more evident in the group of
rats treated chronically with GBR 12909 alone, in which Cys trended downward, while a significant
increase in Met level was accompanied by a strong decline in Hcy content. Furthermore, in the GBR
12909-treated group an increase in GSH content was observed. In turn, combined administration of
BSO + GBR 12909 caused both a much stronger Met level increase and Hcy decrease than did each
of these model compounds administered alone. However, at such conditions, the level of Cys was
slightly higher while GSH content was drastically reduced when compared to the group treated with
GBR 12909 alone. The above-discussed data indicate that inhibition of GSH synthesis in the rat liver
may lead to reduced activity of transsulfuration pathway in this tissue.
As to Cys concentration in the kidney of 16-day-old rats receiving a chronic dose of BSO alone or
in combination with GBR 12909, Cys levels were significantly reduced when compared to the control.
Under physiological conditions, the liver releases the substantial amount of GSH into the blood to
supply other organs [69]. Indeed, the kidney removes about a half of the GSH exported by the liver,
and due to having a high activity of γ-GT and dipeptidase, releases a comparable amount of Cys into
the general circulation [61,69]. Since the decline in Cys content in the kidney of BSO-treated animals
corresponded well with that of GSH, it is clear that degradation of GSH is the main source of Cys in
the kidney. This effect also indicates that inhibition of GSH synthesis impairs liver-kidney inter-organ
coordinated GSH metabolism.
3.2.2. Modifications in Met and Hcy Concentrations
As to Met metabolism in the studied tissues, the liver is the main producer of GSH and
an organ with the highest activity of Met metabolizing enzymes (see description to Figure 10).
In the liver, at physiological conditions when Met is needed, re-methylation of Hcy to Met increases.
Conversely, when Met is in excess, Hcy catabolism via the transsulfuration pathway is intensified [50,70].
The distribution of Hcy between the two competitive reactions provides a major regulatory locus for
the metabolism of sulfur amino acids in the liver [49]. Therefore, one of the main roles of sulfur amino
acid metabolism in the liver is to maintain the appropriate Met level [71,72].
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Figure 10. Hepatic metabolic pathways of Met. In the liver, dietary Met is activated by conversion to SAM
in an ATP-dependent reaction catalyzed by methionine adenosyltransferase (MAT) SAM (approximately
98%) is preferentially used as a donor of methyl groups for different methyltransferases that transfer
them to a variety of acceptor substrates (nucleic acids, proteins, phospholipids, and neurotransmitters)
with the simultaneous formation of S-adenosylhomocysteine (SAH) that is further hydrolyzed, by
S-adenosylhomocysteine hydrolase (SAHH) to yield Hcy and adenosine. The latter reaction is readily
reversible and may cause a chronic elevation of Hcy level. Under normal conditions, Hcy can be
either converted into cystathionine by the transsulfuration pathway or used again for the synthesis of
Met. Cystathionine is converted to Cys via metabolic reactions mediated by cystathionine β-synthase
(CBS) and cystathionine γ-lyase (CSE), consecutively. In the liver, there are two separate remethylation
reactions catalyzed by betaine homocysteine methyltransferase (BHMT) and methionine synthase (MS).
In the liver, methyl groups used for Hcy re-methylation are provided by both methyl tetrahydrofolate
(MTHF) and by the oxidative metabolite of choline, betaine, whereas in other tissues only MTHF is
used as a donor of methyl group for MS. The dashed line indicates the lack or weak expression of a
given enzyme in the brain. Abbreviations: DNMT–DNA methyltransferase; GCL–γ-glutamate-cysteine
ligase; GS—glutathione synthetase; THF—tetrahydrofolate, Ser—serine; Vit. B6—vitamin B6; and Vit.
B12—vitamin B12.
In our study, high but varied increases in Met levels in the liver of rats treated with BSO or
GBR 12909, alone or in combination, suggest that both inhibition of GSH synthesis and DA re-uptake
lead to modification of Met metabolism. As to the impact of BSO alone on Met metabolism, it was
demonstrated that in the liver of rats receiving a single dose of this compound, the MAT activity
decreased by almost 60% [73]. Furthermore, a strong positive correlation (r = 0.936) between the
GSH level and MAT activity presented in this study indicates that GSH plays an important role in
the maintaining appropriate activity of the hepatic MAT. Finally, as a result of the reduced MAT
enzymatic activity, it was found that the SAM level in the liver of BSO-treated rats decreased by
40% [73], suggesting abnormalities in methylation reactions in this organ. In line with these data,
we can assume that in our study, an increased Met level in the liver of BSO-treated rats may result
mainly from the reduced MAT activity. However, such explanation does not seem to be valid for GBR
12909-induced increase in the hepatic Met content, because at such treatment conditions GSH level
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increased. It is worth noting that in human liver dopamine (DA) is synthesized from tyramine by
CYP2D6 isoenzyme (corresponding to CYP2D1 in the rat) [74]. An inhibition of DA re-uptake creates
the need for Met, especially for its active metabolite SAM, which serves as a donor of methyl groups
for catechol-O-methyltransferase (COMT) that metabolizes the extracellular DA to 3-methoxytyramine
(3-MT). It should be added that in the mammalian body, the highest COMT activity was observed
in the liver [75]. In our study, a significant rise in Met content in the rat livers receiving GBR 12909
alone, with a simultaneous decline in Hcy level, seems to indicate that the Hcy remethylation to Met
has been intensified. In the light of these data, the highest increase in Met content observed in the
liver of rats treated with BSO + GBR 12909 may result from both BSO-induced decline in MAT activity
and increased Met synthesis by Hcy remethylation. In the latter group, along with the increase in the
Met level, the strongest decline in Hcy content was found. Although Hcy is produced in all cells, its
conversion to Met is differently modulated in tissues other than the liver. Consistently with the above,
the increases in Met concentrations in the kidneys of rats of all studied groups, were accompanied by
some slight downward trends in Hcy levels, indicating that Met synthesis via Hcy remethylation in
this organ was less intense than in the liver.
A high plasma level of Met is found in several genetic disorders, mainly in MAT deficiency,
which causes persistent hypermethioninemia [76]. Hypermethioninemia patients have exhibited
neurological alterations often associated with abnormalities of brain myelination [77], that were also
observed in schizophrenia patients [78,79]. Taking into account the above findings, we hypothesize
that BSO-induced decrease in the hepatic activity of MAT during the early postnatal development
and subsequent transient hypermethioninemia may be a potential factor leading to abnormal
brain myelination and ultimately dysfunctional brain connectivity. Interestingly, it has been
reported that cognitive deficits and clinical symptoms of schizophrenia can be induced via brain
dysconnectivity [80,81].
3.3. Impact of BSO and GBR 12909 on Sulfur Amino Acid Levels in the Studied Brain Structures
In opposite to the liver and kidney, administration of BSO and GBR 12909, alone or jointly,
differently affected concentrations of Cys, Met, and Hcy in the PFC and HIP.
3.3.1. Modifications in Cys Concentrations
Both model compounds administered alone or jointly, increased the total Cys concentration in
the PFC and HIP. The increase in this amino acid contents may be caused by increased import of the
oxidized form of Cys, i.e., (Cys)2 from plasma into the brain [82] or by increased local Cys synthesis
from Hcy via transsulfuration [83]. Although the transsulfuration pathway has been identified in
the brain [83], an increase in Cys content via this route seems to be less likely, because activities of
transsulfuration enzymes, i.e., CBS and especially CSE in this organ are relatively low, much lower
than in the liver. Furthermore, in our study, in all examined groups of rats, despite increases in the
Cys content both in the PFC and HIP, declines in Hcy levels were not observed. On the contrary,
Hcy contents in these groups of rats trended upward or were statistically significantly enhanced when
compared to the control. These data seem to confirm that the increased levels of Cys in the examined
brain structures may result rather from its increased uptake from plasma than from the local synthesis.
Cys poorly penetrates the BBB, therefore, mainly (Cys)2, is transported into the brain. This transport
is principally carried out by the Na+-independent (Cys)2/glutamate antiporter, also known as system
xc–, that mediates the uptake of (Cys)2 in exchange for intracellular glutamate at a 1:1 ratio [84,85].
Inside the BBB, (Cys)2 is readily reduced and then the resulting Cys is transferred from the endothelial
cells into the brain [86]. In the extracellular space, Cys is reoxidized to (Cys)2 and then transported, into
glial cells, through the xc– transport system [84,87]. In astrocytes, (Cys)2 is reduced to Cys, which is
then either used for the GSH synthesis or transferred outside these cells [84]. Functional studies have
indicated that system xc– represents a highly inducible amino acid transport system [84]. Consistently
with the above, in primary rat astrocyte culture, BSO significantly enhanced expression of the xCT
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subunit of the (Cys)2/glutamate antiporter, at protein and mRNA levels, as well as activity of this
transport system [88]. So, we can suspect that in our study in rats treated chronically with BSO, alone
or in combination with GBR 12909, the increased concentrations of the total Cys in the PFC and HIP,
may be associated with an increased expression of the xc– transport system.
Interestingly, an increase in the levels of xCT subunit of the (Cys)2/glutamate antiporter has
been observed in the post-mortem study of the dorsolateral PFC obtained from patients with
schizophrenia [89]. Furthermore, according to the study by Gysin et al. [30], schizophrenic patients
having an impaired GSH synthesis, displayed a decreased total plasma Cys level but increased (Cys)2
content. In contrast to the latter study, Yang et al. [90] demonstrated that in schizophrenic patients
the content of (Cys)2 in serum was decreased while its level in urine was elevated when compared
to values of these parameters in controls. On the other hand, in a more recent study, Wang et al. [91]
demonstrated that in schizophrenic patients, serum Cys levels were significantly higher than in control,
and they were positively correlated with cognitive functions. There was no such correlation in healthy
control patients. The existence of a cause and effect relationship between plasma Cys content and
cognitive functions suggests that in our study the increase in the Cys level in the PFC and HIP,
may be a compensatory mechanism to limit cognitive disturbances. The functional significance of
Cys seems to be confirmed by clinical studies performed in schizophrenic patients, which showed
the beneficial effects of N-acetyl-L-cysteine (NAC), an acetyl derivative of Cys, in alleviating negative
symptoms [92–94].
3.3.2. Modifications in Met and Hcy Concentrations
As to Met and Hcy concentrations in the PFC and HIP, their levels were modulated in a different
manner by the used model compounds than in the liver and kidney.
In the PFC of rats receiving chronically either BSO alone or the combination of BSO + GBR 12909,
significant decreases in Met and no significant changes in Hcy concentrations were observed compared
to control group. However, in the PFC of rats treated chronically with GBR 12909 alone, some slight
but statistically non-significant increase in Met content was accompanied by a significant increase in
the Hcy level.
In the HIP of rats treated chronically only with BSO, the Met level was markedly enhanced but
Hcy content was maintained at the control level. In turn, in rats receiving GBR 12909 alone, both Met
and Hcy contents were significantly increased. However, in group of rats receiving BSO + GBR 12909,
Met content did not differ significantly from that in control but Hcy was significantly enhanced. These
data show that in the PFC and HIP under conditions of chronic treatment with BSO and GBR 12909,
alone or jointly, metabolic relationship between Met and Hcy are much more complicated than in
peripheral tissues.
It should be reminded that Hcy is produced by the hydrolysis of SAH in a reversible reaction
catalyzed by SAHH (description to Figure 10). This reaction proceeds in the forward direction, as long
as Hcy is efficiently removed via the remethylation or the transsulfuration pathways. However, under
conditions when there is imbalance between these two metabolic pathways and Hcy content rises,
its conversion into SAH is favored. SAH is not only the end product of many transmethylation reactions
but also an inhibitor of different methyltransferases, including DNA methyltransferases, to which it
binds with a higher affinity than SAM. Therefore, to assess the short- and long-term consequences
of Met and Hcy content fluctuations in the studied brain structures, the analysis of the global DNA
methylation was performed in the PFC and HIP, both in 16-day-old rats in the presence of model
compounds, and in addition, in 93-day-old rats, after their withdrawal.
3.4. Impact of BSO and GBR 12909 on the Total DNA Methylation in the Studied Brain Structures
DNA methylation is one of the main epigenetic phenomena serving to establish and maintain
tissue-specific pattern of gene expression. It plays a particularly important role in embryonic and
postnatal development, therefore, disturbances in its course in these periods, may have functional
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consequences. Consistently, the locus-specific DNA hypomethylation is implicated in the etiology
of various cancers and developmental syndromes. On the other hand, DNA hypermethylation that
involves regions of CpG islands located at gene promoters may also be deleterious, as it results in
transcriptional silencing the associated genes [95].
In our study, in the PFC of 16-day-old rats, both in the group treated with BSO or GBR 12909
alone, the global DNA methylation was significantly reduced, and only in the group receiving BSO +
GBR 12909 its level was almost the same as in control. According to the study by Chamberlin et al. [96],
hypomethylation can occur in the absence of changes in the Hcy concentration, under conditions in
which the enzymatic activity of MAT is inhibited. On the other hand, Yi et al. [97] showed that chronic
elevation in plasma SAH content, secondary to an increase in plasma total Hcy, strongly correlated
with DNA hypomethylation in lymphocytes. In the light of these data, we can speculate that in our
study chronic treatment with BSO alone reduces MAT activity not only in the liver [73] but also in
the PFC and finally leads to hypomethylation. In turn, in rats treated chronically with GBR 12909,
hypomethylation can be associated with enhanced SAH content consequent to the increased Hcy level.
In the HIP, the global DNA methylation was significantly increased in rats receiving jointly BSO +
GBR 12909 while in groups treated with BSO or GBR 12909 alone, it was maintained at the control level.
The obtained results indicate that model compounds exert a significant impact on the global DNA
methylation, and their effects are specific for the studied brain structure. Although in the present study
the functional consequences of these direct changes in the global DNA methylation were not further
analyzed in 16-day-old rats, we can speculate that DNA hypo- or hypermethylation during early
postnatal life may be somehow related to the deregulated expression of some genes, which in adulthood
play an important role in revealing schizophrenia-like symptoms. Regarding the long-term effects of
treatment with these model compounds, only the administration of BSO alone during early postnatal
development led at adulthood to aberration in global DNA methylation, i.e., hypermethylation in the
PFC and hypomethylation in the HIP.
3.5. Impact of BSO and GBR 12909 on the Schizophrenia-Like Behavior
The long-term alterations in the global DNA methylation pattern in the studied brain structures of
BSO-treated rats occurred parallel to deficits in the social behavior and in cognitive functions, assessed
in the SIT and NOR tests, respectively. The social and cognitive deficits were also observed in BSO +
GBR 12909-treated group in which there were no significant changes in the global DNA methylation in
the PFC and HIP. However, the lack of such changes in the global DNA methylation in this group of
rats does not necessarily mean that the expression of at least, some specific genes has not been altered
by hyper- or hypomethylation. In line with the latter assumption, our preliminary data showed that the
brain-derived neurotrofic factor (BDNF) protein expression in the PFC and HIP of all groups of adult
rats, which were treated with BSO or GBR 12909 during early postnatal life was markedly reduced in
adulthood [98], suggesting hypermethylation of BDNF gene. The above-discussed behavioral results
indicate that inhibition of GSH synthesis in Sprague–Dawley rats during early postnatal life is a key
factor that initiates a cascade of events, involving changes in the metabolism of sulfur amino acids and
DNA methylation, which in adulthood, lead to development of social deficits corresponding to negative
symptoms and to cognitive impairment observed in schizophrenic patients. In contrast to BSO-treated
groups, rats receiving only GBR 12909 did not show in adulthood either deficit in social behavior and
cognitive functions or in the global DNA methylation. On the other hand, only rats treated in the
early postnatal life with the BSO + GBR 12909 combination showed behavioral changes assessed in
the OFT test in adulthood, corresponding to the positive symptoms seen in schizophrenic patients.
This observation clearly indicates that only changes both in the content of GSH and dopaminergic
transmission during the early postnatal life lead in adult rats to manifestation of behavioral changes
reminiscent of positive symptoms of schizophrenia.
Since a growing body of experimental data shows the aberrant DNA methylation in schizophrenic
patients [6,99], further studies are needed to establish which of the candidate genes suspected to be
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involved in the development of schizophrenia were aberrantly methylated in the neurodevelopmental
model of this disease induced by administration of BSO alone or combination of BSO + GBR 12909.
This experimental approach will allow us to determine the differences in methylation of genes
responsible for negative symptoms and cognitive deficits from methylation of genes responsible for
positive symptoms.
In closing, our results suggest that transient changes in the content of GSH and sulfur amino acid
Met during the early postnatal life lead to alterations in epigenetic status in the PFC and HIP in adult
rats, and to the occurrence of schizophrenic-type social and cognitive deficits. This is summarized in
Figure 11.
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Sciences (permission no 3/2018 of 11 January 2018).All efforts were made to minimize the number and
suffering of animals used.
4.1. Animals a Treatment
Pregnant Sprague–Dawley females at embryonic day 16 delivered by Charles River Company
(Sulzfeld, Germany) were kept in an individual cages under standard laboratory conditions; at room
tempe ature (22 ◦C) under an artificial light/da k cy le (12/12; lights on from 7 am, lights ff from
7 pm), with f ee access to standard laboratory chow and tape water. On the day f birth, the sex of
pups w s d termined, and o ly males were left with their mothers to be used in further experimental
rocedure. B tween the post atal days p5 and p16, m le Sprague–Dawley pups were treated with BSO
(3.8 mmol/kg s.c., daily), the selective inhibitor of GCL, and the DAT inhibitor GBR 12909 (5 mg/kg s.c.,
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every second day), alone or in combination. Control pups instead of the BSO or GBR 12909 were given
vehicle. Rats were weighed daily and the injected quantity was adjusted accordingly to the actual
body weight. On postnatal day p23 rats were weaned and housed in groups of four to five until p92.
Experiments were performed on several groups of rats. Determination of the levels of GSH
and sulfur amino acids (Cys, Met, and Hcy), in the peripheral tissues (liver and kidney), and in the
brain structures (PFC and HIP) was performed in 16-day-old male pups. Behavioral tests (SIT, NOR,
and OFT) evaluating expression of schizophrenia-like symptoms were carried out in adulthood (at
p90–92 days of age). The levels of DNA methylation were determined in the PFC and HIP in both
16-day-old rats, which were killed 4 h after the last doses of the model compounds and in adult
93-day-old rats killed on the next day after the last behavioral test.
4.2. Chemicals and Reagents
GSH Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA,
Item No. 703002) was purchased from Biokom (Warsaw, Poland),
1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR
12909) from Abcam Biochemicals (Cambridge, UK) while the GenElute™ Mammalian Genomic
DNA Miniprep Kit and Imprint®Methylated DNA Quantification Kit from Sigma Aldrich Chemical
Company (St. Louis, MO, USA).
l-buthionine-(S,R)-sulfoximine (BSO), l-cysteine hydrochloride (l-Cys*HCl), glutathione
(GSH), methionine (Met), homocysteine (Hcy), N-acetyl-cysteine (NAC), O-phthaldialdehyde
(OPA), tris-(2-carboxyethyl)phosphine (TCEP), trichloroacetic acid (TCA), 2,7-dichlorofluorescein
(DCF), 2,7-dichlorofluorescein diacetate (DCFH-DA), p-phenylenediamine (pfda), iron(III) chloride
(FeCl3), iron(III) chloride hexahydrate (FeCl3 × 6H2O), iron(II) sulfate heptahydrate (FeSO4
× 7H2O), dithiothreitol (DTT), sodium hydrosulfide (NaHS), sodium sulfide (Na2S), sodium
hydroxide (NaOH), sodium acetate, EDTA, potassium thiocyanate (KSCN), α-ketobutyric acid,
3-methyl-2-benzothiazolinone hydrazine hydrochloride monohydrate (MBTH), pyridoxal 5′-phosphate
monohydrate (PLP), L-homoserine, 2,4,6-tris(2-pyridyl)-s-triazine (TPTZ), thionine, zinc acetate,
albumin bovine, and gelatin were received from Sigma-Aldrich Chemical Company (St. Louis, MO,
USA).
2-Chloro-1-methylquinolinium tetrafluoroborate (CMQT) was prepared in the Department of
Environmental Chemistry, University of Łódź (Łódź, Poland) according to the procedure described by
Bald and Głowacki [100].
Sodium hydroxide (NaOH), HPLC-grade acetonitrile (ACN), sodium hydrogen phosphate
heptahydrate (Na2HPO4 × 7H2O), sodium dihydrogen phosphate dihydrate (NaH2PO4 × 2H2O)
were from J.T. Baker (Deventer, The Netherlands), while perchloric acid (PCA), ninhydrin sodium,
and potassium cyanide (KCN) were obtained from Merck (Darmstadt, Germany). Acetic acid
(CH3COOH), barium chloride (BaCl2), hydrochloric acid (HCl), ammonia (NH3), formaldehyde,
potassium dihydrogen phosphate (KH2PO4), sodium sulfate (Na2SO4), and Folin-Ciocalteu phenol
reagent were purchased from Polish Chemical Reagent Company (P.O.Ch, Gliwice, Poland).
4.3. Biochemical Methods
4.3.1. Preparation of Tissue Homogenates
The frozen tissues were weighted and immediately homogenized using an IKA-ULTRA-TURRAX
T10 homogenizer (IKA Poland Sp. Z o.o company, Warsaw, Poland) at an operating speed of 6000 rpm.
Tissue homogenates were prepared in two ways. The samples of brain structures (prefrontal cortex
and hippocampus), liver, and kidney for HPLC analysis were homogenized in 0.2 M phosphate buffer,
pH 8.2 at the ratio 1:10 (w/v, g/mL) for 0.5 min. The livers and kidneys for other analyzes were
homogenized in 0.1 M phosphate buffer, pH 7.4 at the ratio 1:4 (w/v, g/mL) for 1 min. Homogenates
were then used for biochemical assays.
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4.3.2. Determination of the Total GSH Content in Liver and Kidney Homogenates
Determination of the total GSH in the liver and kidney homogenates was carried out using the
Glutathione Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA), which utilizes carefully
optimized enzymatic recycling method for the quantification of GSH.
The sulfhydryl group of GSH reacts with Ellman’s reagent (5,5′-dithiobis-2-nitrobenzoic
acid-DTNB) and produces a yellow colored 5-thio-2-nitrobenzoic acid (TNB). The second product of
the reaction, mixed disulfide GSTNB, is reduced by GSSG reductase to recycle the GSH and produce
more TNB. The rate of TNB production is directly proportional to the concentration of GSH in the
sample. The absorbance of TBN is measured at 410 nm.
Briefly, 150 µL of freshly prepared assay mixture (NADPH, GSSG reductase, MES buffer consisting
of 0.4 M 2-(N-morpholino)ethanesulfonic acid, 0.1 M phosphate, and 2 mM EDTA, pH 6.0, and DTNB)
were added to 50 µL of homogenate after deproteinization. Incubation was carried out in the dark and
the absorbance was read after 6 min. The GSH concentration was calculated from a standard curve
prepared with 25 µM of GSSG and was expressed in nmoles of GSH per g tissue.
4.3.3. Determination of the Cys Level in Liver and Kidney Homogenates
The levels of Cys were assayed by colorimetric reaction with ninhydrin solution [101]. To 0.95 mL
of homogenate, 0.05 mL of 50% TCA was added, and centrifuged at 10,000× g for 10 min at 4 ◦C.
Subsequently, to 0.125 mL of supernatant, the following reagents were added: 0.125 mL of 2.5% TCA,
0.125 mL of 99.5% acetic acid, and 0.125 mL of ninhydrin reagent (250 mg of ninhydrin, 6 mL of acetic
acid, and 4 mL of hydrochloric acid). The reaction mixture was incubated in a boiling-water bath for
10 min, cooled, and then 0.5 mL of ethanol was added. Absorbance was measured at 560 nm. The Cys
concentration was calculated from a standard curve prepared for 1 mM l-Cys*HCl and was expressed
in nmoles per g tissue.
4.3.4. Determination of Sulfur Amino Acids in the Rat Tissues Using the HPLC Method
Determination of Total GSH and Cys Levels in the Brain Structures
Assay procedure for tissues:
Total GSH and Cys levels in the brain samples (PFC and HIP) were analyzed by high-performance
liquid chromatography (HPLC) with ultraviolet (UV) detection according to the method described by
Bald et al. [102] with a modification developed by Kamińska et al. [103]. Simultaneous determination
of thiols was carried out using HPLC after precolumn derivatization with CMQT [100].
Briefly, 100 µL of the appropriate brain structure tissue homogenate (PFC and HIP) was incubated
with 7.5 µL of 0.25 M Tris-(2-carboxyethyl)phosphine (TCEP) solution at room temperature for
15 min in order to reduce disulfide bonds. Next, 10 µL of 0.1 M CMQT was added, vortexed
and kept at room temperature for 5 min. The mixture was acidified with 15 µL of 3 M perchloric
acid (PCA). The precipitated proteins were removed by centrifugation at 12,000 rpm for 10 min at
10 ◦C. The supernatant samples (10 µL) were injected (using an autosampler) into the HPLC system
(1220 Infinity LC system from Agilent, Waldbronn, Germany) equipped with Zorbax SB-C18 column
(Agilent Technologies), a diode-array detector and controlled by OpenLAB CDS ChemStation Edition
software (Rev. C.01.05, Agilent Technologies, Waldbronn, Germany). Each sample was analyzed in
duplicate. The mobile phase consisted of 0.1 M trichloroacetic acid (TCA) adjusted by 1M NaOH
to pH = 1.6 (A) and acetonitrile (B). The flow-rate was 1 mL/min, temperature 25 ◦C and detector
wavelength 355 nm. For separation of the 2-S-quinolinium derivatives of thiols from each other and
from reagent excess the following gradient elution was used: 0–3.5 min, 11%–25% (B); 3.5–5.5 min,
25%–40% (B); and 5.5–9 min 40%–11% (B).
Identification of GSH and Cys peaks was based on the comparison of retention times and
diode-array spectra with the corresponding set of data obtained for standard compounds. GSH and
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Cys concentrations were read from a calibration curve prepared from GSH (0–300 nmol/mL) and Cys
(0–30 nmol/mL), and were expressed in nmoles GSH or Cys per g tissue, respectively.
Determination of Met and Hcy Levels in the Liver, Kidney, and Brain Structures
Assay procedure for tissues:
Met and Hcy levels were determined by HPLC method with fluorescence (FL) detection
described by Borowczyk et al. [104] with some modifications. This HPLC-FL method is based
on an on-column derivatization with O-phthaldialdehyde (OPA) and is used for the determination of
thiols in biological samples.
Briefly, 100 µL of homogenate was treated with 14 µL of 0.25 M Tris-(2-carboxyethyl)phosphine
(TCEP) solution for 10 min at room temperature in order to reduce disulfide bonds. Then, 30 µL of 0.5 M
N-acetyl-cysteine (NAC) solution and 10 µL of 3 M perchloric acid (PCA) were added and the mixture
was vortexed and centrifuged at 12,000 rpm at 10 ◦C for 10 min. The supernatant was transferred into
HPLC system. HPLC analysis was performed on the HPLC system (1100 series from Hewlett-Packard,
Waldbronn, Germany) equipped with FL detector (1260 Series from Agilent Technologies, Waldbronn,
Germany) and controlled by HP ChemStation software (Rev. A.10.02, Hewlett-Packrd, Waldbronn,
Germany). The samples of supernatant (5 µL) were injected into the column PRP-1 Hamilton
(150 nm × 4.6 nm × 5 µm) and each sample was analyzed in duplicate. The mobile phase consisted
of 0.01 M OPA in 0.1 M NaOH and acetonitrile in the gradient mode described earlier [104] and was
applied at the flow rate 1 mL/min. Amounts of Met and Hcy were quantified by using an FL detector
at two different excitation and emission wavelengths (0–8 min excitation at 348 nm and emission
at 438 nm and 8–14 min excitation at 370 nm and emission at 480 nm). Identification of peaks was
based on comparison of retention time with data obtained for standard compounds. The levels of
Met and Hcy were evaluated using the calibration curves prepared for Met (0–20 nmol/mL) or Hcy
(0–7 nmol/mL) and finally were expressed in nmoles Met and Hcy per g tissue, respectively.
4.3.5. Measurement of the Global DNA Methylation
High-quality and ultra-pure genomic DNA (without any RNA contamination) was extracted from
prefrontal cortex and hippocampus using the GenElute™Mammalian Genomic DNA Miniprep Kit
according to the manufacturer’s instructions. Global changes in DNA methylation were measured in
the tested tissue samples using a specific ELISA-based Kit (Imprint®Methylated DNA Quantification).
The quantity and quality of DNA was spectrophotometrically measured at 260 nm and 260/280 nm
(ND/1000 UV/VIS; Thermo Fisher NanoDrop, Waltham, MA, USA) [105,106]. This kit contained
all the reagents required to determine the relative levels of methylated DNA, including control
methylated DNA. Methylated DNA was detected using capture and detection antibodies and quantified
colorimetrically using an Infinite M200pro microplate reader (Tecan, Austria). The amount of
methylated DNA present in the sample was proportional to the absorbance measured.
4.4. Behavioral Methods
4.4.1. Social Interaction Test
The social interaction test (SIT) was performed using a black PCV box (67 cm × 57 cm × 30 cm,
length × width × height). The arena was dimly illuminated with an indirect light of 18 Lux [107].
Each social interaction experiment involving two rats was carried out during the light phase of the
light/dark cycle. The rats were selected from separate housing cages to make a pair for the study.
The paired rats were matched for body weight within 15 g. Rats of each pair were placed diagonally in
opposite corners of the box facing away from each other. The behavior of the animals was measured
over a 10-min period. The test box was wiped clean between each trial. Social interaction between two
rats was expressed as the total time spent in social behavior, such as sniffing, genital investigation,
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chasing, and fighting with each other. The number of episodes was counted as a separate paradigm.
The SIT test was performed on day p90. Each group was composed of 12 rats (six pairs).
4.4.2. Novel Object Recognition Test
The novel object recognition (NOR) test was performed using a black PCV box
(67 cm × 57 cm × 30 cm, length ×width × height). The arena was dimly illuminated with an indirect
light of 18 Lux. On the first day of the experiment (adaptation), a rat was placed in the box for 10 min.
On the next day, the animal was placed in the box for 5 min (T1) with two identical objects (white tin
5 cm wide and 14 cm high or green pyramid 5 cm wide and 14 cm high). The exploration time of
objects was measured for each of the two objects separately. Then, one hour after T1, each rat was
again placed in the box for 5 min (T2), with two different objects: one of the previous session (old) and
the other new (white box and green pyramid). The exploration time of objects was measured for each
of the two objects separately (sniffing, touching or climbing). The NOR test was performed on day p91.
Each group was composed of 10 rats.
4.4.3. Open Field Test
Exploratory activity was assessed in the elevated OFT. A black circular platform without walls
having 1 m in diameter was divided into six symmetrical sectors and was elevated 50 cm above the
floor. The laboratory room was dark and only the centre of the open field was illuminated with a 75 W
bulb placed 75 cm above the platform. At the beginning of the test, the animal was placed gently in
the centre of the platform and was allowed to explore. The exploratory activity, ambulation, peeping,
and rearing in the open field, i.e., respectively, the time of walking, the number of sector crossings,
and the number of episodes of peeping under the edge of arena and rearing were assessed for 5 min.
The OFT test was performed on day p92. Each group consisted of 10 rats.
4.5. Statistics
The statistical analysis of the obtained biochemical and behavioral data was performed using a
two-way ANOVA followed (if significant) by the Newman–Keuls test for post-hoc comparisons.
Supplementary Materials: The following are available online; Figure S1. Representative chromatogram for Met
and Hcy assay in the liver homogenate; Figure S2. Representative chromatogram for Met and Hcy assay in the
kidney homogenate; Figure S3. Representative chromatogram for GSH and Cys assay in the PFC homogenate;
Figure S4. Representative chromatogram for Met and Hcy assay in the PFC homogenate; Figure S5. Representative
chromatogram for GSH and Cys assay in the HIP homogenate; Figure S6. Representative chromatogram for Met
and Hcy assay in the Hip homogenate. All chromatograms refer to tissue homogenates of control rats.
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